ImClone will be able to use phage display tool for another four years.
Dyax extended an antibody library collaboration for another four years with ImClone Systems for the discovery of therapeutic antibodies. ImClone will continue to have the rights to access Dyax’ phage display technology.
ImClone reports that it has three drugs in its pipeline, fully human mAbs against EGFR, IGF-1R, and KDR, that have successfully advanced into Phase II trials using Dyax’ technology.
“This extended agreement with ImClone,” comments Henry E. Blair, chairman, president, and CEO of Dyax, “validates the strength of our proprietary technology in successfully identifying human monoclonal antibodies in key therapeutic areas.”